RAPT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 158896 min ago

@ $24.99

Išleistas: 13 vas. 2024 @ 22:43

Grąža: -83.95%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 0.73 %

Live Chart Being Loaded With Signals

Commentary (31 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	906 472
Vidutinė apimtis	946 625
Rinkos kapitalizacija	139.96M
EPS	$0 ( 2024-05-22 )
Kita pelno data	( $-0.740 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.300
ATR14	$0.00700 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-22	Robbins Wendye	Buy	36 490	Stock Option (right to buy)
2024-05-23	Rieflin William Jl	Buy	36 490	Stock Option (right to buy)
2024-05-22	Lyons-williams Lori	Buy	36 490	Stock Option (right to buy)
2024-05-22	Kozick Linda	Buy	36 490	Stock Option (right to buy)
2024-05-22	Gray Mary Ann	Buy	36 490	Stock Option (right to buy)

INSIDER POWER
95.05
Last 100 transactions
Buy: 1 453 799 \| Sell: 63 895

Tūris Koreliacija

Ilgas: -0.48 (neutral)

Trumpas: 0.53 (weak)

Signal:(32.787) Neutral

Rapt Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CYAN	0.945
LTRX	0.943
QDEL	0.94
WISA	0.938
IMKTA	0.938
SSRM	0.932
HFFG	0.931
VLCN	0.93
KRKR	0.93
AMCX	0.93

10 Labiausiai neigiamai susiję koreliacijos
MACK	-0.978
MEDP	-0.953
ADSE	-0.95
CRTO	-0.932
IBKR	-0.928
TXRH	-0.927
FREE	-0.927
SHLD	-0.921
TRVI	-0.917
VSEC	-0.917

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Rapt Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

0.40
( neutral )

-0.49
( neutral )

Rapt Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
Pajamos:	$0
Bruto pelnas:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
Pajamos:	$1.53M
Bruto pelnas:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
Pajamos:	$3.81M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.